Korro Bio is trading 5.3% down today at $12.79 as the stock continues to digest the impact of its failed KRRO-110 program and paused Novo Nordisk RNA partnership.
- Shares are experiencing continued post-trial volatility following the termination of the company's lead program and the suspension of a key strategic collaboration.
- The downward move is being exacerbated by a broader pullback in biotech shares, which is disproportionately pressuring high-beta names after a strong sector rally.